Venture Liquidity Providers

VLP Therapeutics is a clinical-stage biotechnology company focused on developing next-generation vaccines and biologics for infectious diseases and cancer. The company utilizes two primary proprietary platforms: the intercalated Virus-Like Particle (i-VLP) platform, which enhances the immunogenicity of antigens, and a self-amplifying RNA (saRNA) platform designed to provide potent immune responses at lower doses than conventional mRNA. Its lead programs include a malaria vaccine candidate and a COVID-19 vaccine, both of which have entered clinical trials. Headquartered in Gaithersburg, Maryland, VLP Therapeutics operates with a mission to address global health challenges through innovative vaccine design.